Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427283 | 1.00 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL30272608 | 0.91 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL20570922 | 0.91 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL3282383 | 0.89 | GPR119 (0.59) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL848331 | 0.87 | GPR119 (0.57) | GPR119HRH3CHEK2ALDH1A1PDE4A | |
| SCHEMBL3579129 | 0.86 | GPR119 (0.67) | GPR119HRH3CHEK2ALDH1A1PDE4A | |
| SCHEMBL3091210 | 0.86 | GPR119 (0.64) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL214556 | 0.86 | GPR119 (0.56) | GPR119HRH3CHEK2NPBWR1MCHR1 | |
| SCHEMBL30426929 | 0.86 | GPR119 (0.67) | GPR119HRH3CHEK2ALDH1A1PDE4A | |
| SCHEMBL5462103 | 0.85 | GPR119 (0.58) | GPR119HRH3CHEK2NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024131942-A1 | CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239959-A | Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| CN-116745278-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116194455-A | Protein secretion inhibitor | 科智生命科学公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | GPR119 164/4885HRH3 339/4885CHEK2 4317/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | GPR119 2261/4885HRH3 4555/4885CHEK2 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.